Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Infectious & Toxicology
Filter     Order     Display # 
Date Item Title
16 Apr 2008 Novavax Reports Positive Results from Preclinical Studies of its VLP-based
16 Apr 2008 ViroPharma Announces Discontinuation of HCV-796 Development
15 Apr 2008 Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
15 Apr 2008 Pacgen Completes Patient Recruitment for Phase II Dose Ranging Trial of Novel Anti-Fungal Drug
15 Apr 2008 Basilea opens new phase III study in special patient populations for its broad-spectrum antifungal isavuconazole
15 Apr 2008 Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
14 Apr 2008 Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
11 Apr 2008 Arpida provides further comments on the pivotal Phase III trials
10 Apr 2008 Post-exposure vaccination with IMVAMUNE(R) protects against lethal poxvirus infection
09 Apr 2008 Alnylam Initiates Phase II Trial to Evaluate Safety and Tolerability of ALN-RSV01 in Adult Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus (RSV) Infection
09 Apr 2008 Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
08 Apr 2008 Chelsea Therapeutics Gains Global Rights to I-3D Portfolio Targeting Autoimmune Disease and Transplant Rejection
04 Apr 2008 FDA Approves ROTARIX(R) Rotavirus Vaccine
03 Apr 2008 Crucell Announces First in Man Study with New Adenovirus Vector
03 Apr 2008 Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
02 Apr 2008 Sinovac Biotech Ltd. (SNVBF) Receives SFDA Approval for Pandemic Influenza H5N1 Vaccine
01 Apr 2008 AVANT's Single-Dose Oral Ty800 Vaccine Meets Primary Endpoints in Phase 2 Study
01 Apr 2008 InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
31 Mar 2008 Sharing of Sabin-IPV Seed Virus by Japan Poliomyelitis Research Institute with Takeda and Grant of Right to Its Commercialization
31 Mar 2008 Crucell Announces Start of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US
31 Mar 2008 Argos Therapeutics Presents Positive Phase 1 Safety Data for its Arcelis Platform in HIV at Keystone Symposia
27 Mar 2008 GTC Biotherapeutics and PharmAthene Extend Agreement for Protexia Program
27 Mar 2008 Thallion provides update on Shigamabs (R) program
27 Mar 2008 SIGA Successfully Completes ST-246 Multiple Ascending Dose Human Clinical Trial
25 Mar 2008 Ceragenix Enters into Agreement to License CSA-54 and other Ceragenin Compounds To Biopharmaceutical Company for HIV and STD Applications
25 Mar 2008 Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage
24 Mar 2008 BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
20 Mar 2008 Presidio Pharmaceuticals Obtains Exclusive Worldwide Rights to XTL Biopharmaceuticals Ltd. Hepatitis C Virus (HCV) NS5A Program
20 Mar 2008 Acambis extends Sanofi Pasteur licensing agreement on single-dose JE vaccine to India and Indian subcontinent
20 Mar 2008 NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
20 Mar 2008 Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels
20 Mar 2008 Pharmathene signs definitive agreement to acquire Biodefense vaccines business from Avecia
19 Mar 2008 Medicago’s H5N1 VLP vaccine provides protection against multiple strains of avian flu
19 Mar 2008 Arpida submits New Drug Application for intravenous iclaprim for treatment of skin infections
19 Mar 2008 European CHMP Issues Positive Opinion for Viread(R) for the Treatment of Chronic Hepatitis B
18 Mar 2008 FDA issues Approvable Letter for ceftobiprole, a new anti-MRSA broad-spectrum antibiotic
17 Mar 2008 Phylogica and Dynamic Microbials sign anti-bacterial deal
17 Mar 2008 Hepatitis C Virus DNA Vaccine Shows Safety When Delivered by Inovio Biomedical's Electroporation Delivery System in Phase I/II Clinical Study at Karolinska University Hospital
17 Mar 2008 iCo Therapeutics iCo-009 (Oral Amphotericin B) Published in Leading Drug Delivery Journal
17 Mar 2008 NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
17 Mar 2008 Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
17 Mar 2008 Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV
13 Mar 2008 MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
13 Mar 2008 Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 'ADVANCE' Study with Telaprevir in Treatment-Naive, Genotype 1 HCV Patients
12 Mar 2008 Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
11 Mar 2008 Optimer Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of Prulifloxacin in Patients with Travelers’ Diarrhea
11 Mar 2008 OctoPlus announces publication of Phase I Locteron results in the Journal of Interferon and Cytokine Research
07 Mar 2008 Gilead Sciences Submits Marketing Authorisation Application for Aztreonam Lysine 75 mg Powder for Nebuliser Solution, a Potential New Treatment for Cystic Fibrosis, to European Medicines Agency
06 Mar 2008 PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
06 Mar 2008 AVANIR Pharmaceuticals Licenses Anthrax Monoclonal Antibody Program to Emergent BioSolutions
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 251 - 300 of 1267

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics